STOCK TITAN

Organogenesis Holdings (ORGO) Stock News, May-Aug 2020

ORGO NASDAQ

Organogenesis Holdings Inc. develops, manufactures and sells regenerative medicine and tissue-innovation products for the Advanced Wound Care and Surgical & Sports Medicine markets. News about the company commonly covers product revenue by those markets, gross margin and profitability trends, and corporate updates tied to its Nasdaq-listed Class A common stock.

Company updates also focus on clinical and regulatory activity across its portfolio. Recurring subjects include PuraPly AM clinical evidence in diabetic foot ulcers, ReNu as a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis, FDA interactions, Biologics License Application activity, and coverage or payment developments affecting skin-substitute and wound-care products.

Rhea-AI Summary

Organogenesis Holdings Inc. (Nasdaq: ORGO) announced the resignation of CFO Timothy M. Cunningham effective August 18, 2020. His departure was not due to disputes or financial issues. Henry Hagopian, previously Vice President of Finance, has stepped in as interim CFO while a national search for a permanent replacement begins. CEO Gary S. Gillheeney acknowledged Cunningham's role in the company's progress and public transition. Hagopian brings extensive financial experience, including previous roles at CIRCOR International and Lucent Technologies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.84%
Tags
none
-
Rhea-AI Summary

Organogenesis Holdings Inc. (ORGO) reported a net revenue of $69 million for Q2 2020, an increase of 6% year-over-year. Revenue from Advanced Wound Care products rose 8% to $59.7 million, while Surgical & Sports Medicine products declined by 5% to $9.2 million. The net loss improved to $5.2 million from $9.6 million in Q2 2019. Adjusted EBITDA was $274,000, up from a loss of $4.8 million. The company reinstated its 2020 revenue guidance for 5%-6% growth, reflecting strong operational fundamentals despite the COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.19%
Tags
-
Rhea-AI Summary

Organogenesis Holdings (Nasdaq: ORGO) announces participation as a Platinum Sponsor at the 2020 Symposium on Advanced Wound Care (SAWC) Virtual Experience from July 24-26. The company's advanced wound care research, including products like Apligraf and Dermagraft, will be showcased. Highlights include an Innovation Theater event and multiple virtual Private Networking Suites for attendees to engage with experts. Key poster presentations cover studies on various wound treatments, including living cellular constructs and collagen dressings for venous leg ulcers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.84%
Tags
conferences
Rhea-AI Summary

Organogenesis Holdings Inc. (Nasdaq: ORGO) has scheduled its second quarter 2020 financial results announcement for August 10, 2020, after market close. A conference call will follow at 5:00 p.m. ET, providing updates and a question and answer session. Investors can join by dialing 866-795-3142 or via a live webcast on the company’s investor relations website. A replay will be available for two weeks. Organogenesis specializes in regenerative medicine products for Advanced Wound Care and Surgical markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.52%
Tags
conferences earnings
-
Rhea-AI Summary

Organogenesis Holdings Inc. (Nasdaq: ORGO) reported net revenue of $61.7 million for Q1 2020, an increase of 8% from $57.1 million in Q1 2019. Advanced Wound Care products generated $51.3 million, up 7%, while Surgical & Sports Medicine products increased 13% to $10.4 million. Despite revenue growth, the company recorded a net loss of $16.3 million, compared to a $15.7 million loss a year earlier. The company withdrew its fiscal year 2020 revenue guidance due to uncertainty from the COVID-19 pandemic, prioritizing cost-saving measures.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.73%
Tags

FAQ

What is the current stock price of Organogenesis Holdings (ORGO)?

Organogenesis Holdings (ORGO) last closed at $0.8532.

What is the market cap of Organogenesis Holdings (ORGO)?

The market cap of Organogenesis Holdings (ORGO) is approximately $110.7M.